Andere Sprachen Bayer AG

Aktien

BAY001

DE000BAY0017

BAYN

Pharmazeutika

Realtime-Estimate Tradegate Andere Börsenplätze 17:26:19 12.12.2025			% 5 Tage	Veränd. 1. Jan.
36.57 ^EUR	+0.45%		+9.58%	+88.96%

16:38	Bayer erhält Empfehlung eines EU-Ausschusses für neue Indikation seines Augenmedikaments	MT
15:30	Bayer-Augenmedikament Eylea vor EU-Zulassung in weiterer Indikation	DJ

Andere Sprachen

Bayer Wins EU Panel's Recommendation for Eye Disease Drug's New Indication	16:38
Bayer : Aflibercept 8 mg recommended for EU approval for third retinal indication	15:03
DCM Shriram and Bayer sign MoU for agriculture	10.12.
Bayer : AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan	09.12.
Sumitomo Corporation acquired Metribuzin Solo Business in Latin America, Asia-Pacific and Canada of Bayer Aktiengesellschaft.	09.12.
Les Bourses mondiales concentrées sur la politique monétaire de la Fed	08.12.
Galmed Pharmaceuticals Ltd. Announces Acceptance of Late-Breaking Abstract to Be Presented at HEP-DART 2025 Meeting	08.12.
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	05.12.
Bayer lance une étude de Phase IIa dans le syndrome d'Alport	05.12.
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	04.12.
Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug	04.12.
Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome	04.12.
Bayer : MediaBayer starts Phase IIa study for treatment of patients with Alport Syndrome	04.12.
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome	04.12.
Bayer Reveals First Results of the Pediatric Study from the Pivotal Clinical Development Program Quanti for Its Low-Dose Mri Contrast Agent	03.12.
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints	03.12.
Bayer: study for gadoquatrane in children meets primary, secondary endpoints	03.12.
Bayer's Gadoquatrane Shows Promise in Pediatric Trial	03.12.
Bayer : Data from Pediatric Study for Bayer's Investigational MRI Contrast Agent presented at RSNA 2025	03.12.
Health Care Down, as Traders Seek Out Risk - Health Care Roundup	02.12.
Les marchés scrutent les données économiques et les développements géopolitiques	02.12.
Bolsas europeas cierran con pocos cambios y Bayer sube gracias a respaldo en EEUU	02.12.
Les Bourses mondiales prudentes, entre Ukraine et données économiques à venir	02.12.
Point marchés-L'Europe finit sans tendance une séance dominée par l'attentisme	02.12.
Bayer Shares Surge Fuels German DAX Index Gains	02.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

BAYER : Märkte begrüßen über den Erwartungen liegendes Q3 und keine negativen Überraschungen

Am 12. November 2025 um 19:03 Uhr

Bayer: Kurz vor dem letzten Round(up)?

Am 05. Juni 2025 um 18:18 Uhr